Limited Availability of Nirsevimab in the U.S.

An “unprecedented demand” for nirsevimab has led to limited supply for the 2023-2024 RSV season. Nirsevimab is an FDA-approved monoclonal antibody product recommended for preventing respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD) in infants. In collaboration with the CDC, the manufacturers aim for equitable distribution of available doses through the Vaccines For Children Program.

The CDC recommends prioritizing available 100 mg doses of nirsevimab for infants at the highest risk for severe RSV disease. Providers advised to discuss RSVpreF maternal vaccine to reduce infants needing nirsevimab during RSV season. Read more from the CDC here.